Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 561852, 6 pages
http://dx.doi.org/10.1155/2013/561852
Review Article

Immunotherapy Treatments of Warm Autoimmune Hemolytic Anemia

Department of Immunology, Zunyi Medical College, Zunyi, Guizhou 563003, China

Received 25 February 2013; Revised 31 July 2013; Accepted 13 August 2013

Academic Editor: Mark Yazer

Copyright © 2013 Bainan Liu and Wangang Gu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. H. Packman, “Hemolytic anemia due to warm autoantibodies,” Blood Reviews, vol. 22, no. 1, pp. 17–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Stahl and W. Sibrowski, “Warm autoimmune hemolytic anemia is an IgM-IgG immune complex disease,” Journal of Autoimmunity, vol. 25, no. 4, pp. 272–282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. D. Petz and G. Garratty, Eds., Immune Hemolytic Anemias, Churchill Livingstone, New York, NY, USA, 2004.
  4. K. Lechner and U. Jäger, “How i treat autoimmune hemolytic anemias in adults,” Blood, vol. 116, no. 11, pp. 1831–1838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Sokol, D. J. Booker, R. Stamps, J. R. Booth, and V. Hook, “IgA red cell autoantibodies and autoimmune hemolysis,” Transfusion, vol. 37, no. 2, pp. 175–181, 1997. View at Google Scholar · View at Scopus
  6. F. Meyer, L. Garin, C. Smati, M. Gaspard, C. Giannoli, and D. Rigal, “Application of the gel test using and anti-IgA antiglobulin for the immunologic diagnosis of autoimmune hemolytic anemia with a negative direct Coombs test,” Transfusion Clinique et Biologique, vol. 6, no. 4, pp. 221–226, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Barros, M. A. Blajchman, and J. O. Bordin, “Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment,” Transfusion Medicine Reviews, vol. 24, no. 3, pp. 195–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. B. C. Gehrs and R. C. Friedberg, “Autoimmune hemolytic anemia,” American Journal of Hematology, vol. 69, no. 4, pp. 258–271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. K. E. King and P. M. Ness, “Treatment of autoimmune hemolytic anemia,” Seminars in Hematology, vol. 42, no. 3, pp. 131–136, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Michel, “Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults,” Presse Medicale, vol. 37, no. 9, pp. 1309–1318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Valent and K. Lechner, “Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review,” Wiener Klinische Wochenschrift, vol. 120, no. 5-6, pp. 136–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Allgood and H. J. Chaplin, “Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965,” The American Journal of Medicine, vol. 43, no. 2, pp. 254–273, 1967. View at Google Scholar · View at Scopus
  13. B. Zupanska, T. Sylwestrowicz, and S. Pawelski, “The results of prolonged treatment of autoimmune haemolytic anaemia,” Haematologia, vol. 14, no. 4, pp. 425–433, 1981. View at Google Scholar · View at Scopus
  14. L. D. Petz, “Treatment of autoimmune hemolytic anemias,” Current Opinion in Hematology, vol. 8, no. 6, pp. 411–416, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Dacie, “The immune haemolytic anaemias: a century of exciting progress in understanding,” British Journal of Haematology, vol. 114, no. 4, pp. 770–785, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Pogglitsch, H. Warnkross, V. Weinrauch, and H. M. Winkler, “Successful treatment of an autoimmune hemolytic anemia by cyclosporin A,” Wiener Medizinische Wochenschrift, vol. 136, no. 21-22, pp. 567–570, 1986. View at Google Scholar · View at Scopus
  17. S. M. Worlledge, M. C. Brain, A. C. Cooper, J. R. Hobbs, and J. V. Dacie, “Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia,” Proceedings of the Royal Society of Medicine, vol. 61, no. 12, pp. 1312–1315, 1968. View at Google Scholar · View at Scopus
  18. M. E. Reff, K. Carner, K. S. Chambers et al., “Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20,” Blood, vol. 83, no. 2, pp. 435–445, 1994. View at Google Scholar · View at Scopus
  19. D. Shan, J. A. Ledbetter, and O. W. Press, “Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies,” Blood, vol. 91, no. 5, pp. 1644–1652, 1998. View at Google Scholar · View at Scopus
  20. P. Quartier, B. Brethon, P. Philippet, J. Landman-Parker, F. le Deist, and A. Fischer, “Treatment of childhood autoimmune haemolytic anaemia with rituximab,” The Lancet, vol. 358, no. 9292, pp. 1511–1513, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Zecca, B. Nobili, U. Ramenghi et al., “Rituximab for the treatment of refractory autoimmune hemolytic anemia in children,” Blood, vol. 101, no. 10, pp. 3857–3861, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. G. D'Arena, C. Califano, M. Annunziata et al., “Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients,” European Journal of Haematology, vol. 79, no. 1, pp. 53–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Bussone, E. Ribeiro, A. Dechartres et al., “Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases,” American Journal of Hematology, vol. 84, no. 3, pp. 153–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Dierickx, G. Verhoef, A. van Hoof et al., “Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study,” Journal of Internal Medicine, vol. 266, no. 5, pp. 484–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Narat, J. Gandla, A. V. Hoffbrand, R. G. Hughes, and A. B. Mehta, “Rituximab in the treatment of refractory autoimmune cytopenias in adults,” Haematologica, vol. 90, no. 9, pp. 1273–1274, 2005. View at Google Scholar · View at Scopus
  26. T. D. Shanafelt, H. L. Madueme, R. C. Wolf, and A. Tefferi, “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome,” Mayo Clinic Proceedings, vol. 78, no. 11, pp. 1340–1346, 2003. View at Google Scholar · View at Scopus
  27. F. Zaja, I. Iacona, P. Masolini et al., “B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia,” Haematologica, vol. 87, no. 2, pp. 189–195, 2002. View at Google Scholar · View at Scopus
  28. K. R. Carson, A. M. Evens, E. A. Richey et al., “Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project,” Blood, vol. 113, no. 20, pp. 4834–4840, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Barcellini, F. Zaja, A. Zaninoni et al., “Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies,” Blood, vol. 119, no. 16, pp. 3691–3697, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Gobert, J. B. Bussel, C. Cunningham-Rundles et al., “Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients,” British Journal of Haematology, vol. 155, no. 4, pp. 498–508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Conti, C. Perricone, F. Ceccarelli, and G. Valesini, “Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin,” Autoimmunity Reviews, vol. 9, no. 11, pp. 716–720, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Tanaka, K. Yamamoto, T. Takeuchi et al., “A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus,” Modern Rheumatology, vol. 17, no. 3, pp. 191–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Reynolds, V. Toescu, C. S. Yee, A. Prabu, D. Situnayake, and C. Gordon, “Effects of rituximab on resistant SLE disease including lung involvement,” Lupus, vol. 18, no. 1, pp. 67–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. T. Merrill, J. P. Buyon, R. A. Furie et al., “Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER),” Lupus, vol. 20, no. 7, pp. 709–716, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Dierickx, G. Verhoef, A. van Hoof et al., “Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study,” Journal of Internal Medicine, vol. 266, no. 5, pp. 484–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Newman, M. B. Owlia, I. El-Hemaidi, and M. Akhtari, “Management of immune cytopenias in patients with systemic lupus erythematosus—old and new,” Autoimmunity Reviews, vol. 12, no. 7, pp. 784–791, 2013. View at Publisher · View at Google Scholar
  37. T. Robak, “Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders,” Current Opinion in Molecular Therapeutics, vol. 10, no. 3, pp. 294–309, 2008. View at Google Scholar · View at Scopus
  38. J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman et al., “The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20,” Journal of Immunology, vol. 177, no. 1, pp. 362–371, 2006. View at Google Scholar · View at Scopus
  39. I. V. Gupta and R. C. Jewell, “Ofatumumabthe first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies,” Annals of the New York Academy of Sciences, vol. 1263, pp. 43–56, 2012. View at Publisher · View at Google Scholar
  40. A. D. Zelenetz, J. S. Abramson, R. H. Advani et al., “NCCN clinical practice guidelines in oncology: non-Hodgkin’s lymphomas,” Journal of the National Comprehensive Cancer Network, vol. 8, pp. 288–334, 2010. View at Google Scholar
  41. W. G. Wierda, T. J. Kipps, J. Durig et al., “Ofatmumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial,” ASH Annual Meeting Abstracts, vol. 114, article 207, 2009. View at Google Scholar
  42. G. Hale, M. Q. Xia, H. P. Tighe, M. J. Dyer, and H. Waldmann, “THe CAMPATH-1 antigen (CDw52),” Tissue Antigens, vol. 35, no. 3, pp. 118–127, 1990. View at Google Scholar · View at Scopus
  43. A. Treumann, M. R. Lifely, P. Schneider, and M. A. Ferguson, “Primary structure of CD52,” The Journal of Biological Chemistry, vol. 270, no. 11, pp. 6088–6099, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. A. P. Mone, C. Cheney, A. L. Banks et al., “Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism,” Leukemia, vol. 20, no. 2, pp. 272–279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Stanglmaier, S. Reis, and M. Hallek, “Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells,” Annals of Hematology, vol. 83, no. 10, pp. 634–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Willis, J. C. W. Marsh, D. H. Bevan et al., “The effect of treatment with Campath-1H in patients with autoimmune cytopenias,” British Journal of Haematology, vol. 114, no. 4, pp. 891–898, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Karlsson, L. Hansson, F. Celsing, and J. Lundin, “Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody),” Leukemia, vol. 21, no. 3, pp. 511–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Laurenti, M. Tarnani, D. G. Efremov et al., “Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia,” Leukemia, vol. 21, no. 8, pp. 1819–1821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Royer, I. Vaida, A. Etienne, R. Garidi, G. Damaj, and J. P. Marolleau, “Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab,” Leukemia, vol. 21, no. 8, pp. 1841–1842, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Osterborg, C. Karlsson, and J. Lundin, “Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia,” Current Hematologic Malignancy Reports, vol. 4, no. 1, pp. 47–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. J. F. Lambert and U. E. Nydegger, “Geoepidemiology of autoimmune hemolytic anemia,” Autoimmunity Reviews, vol. 9, no. 5, pp. A350–A354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Shinoda, H. Taki, H. Hounoki, R. Ogawa, E. Sugiyama, and K. Tobe, “Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjogren's syndrome,” International Journal of Rheumatic Diseases, vol. 13, no. 1, pp. 94–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Duarte-Rey, D. P. Bogdanos, P. S. Leung, J. M. Anaya, and M. E. Gershwin, “IgM predominance in autoimmune disease: genetics and gender,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A404–A412, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. M. Hall, M. A. Vickers, R. N. Barker, and L. P. Erwig, “Helper T cells point the way to specific immunotherapy for autoimmune disease,” Cardiovascular and Hematological Disorders Drug Targets, vol. 9, no. 3, pp. 159–166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Fagiolo, “Immunological tolerance loss vs. erythrocyte self antigens and cytokine network disregulation in autoimmune hemolytic anaemia,” Autoimmunity Reviews, vol. 3, no. 2, pp. 53–59, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. K. L. Knutson and M. L. Disis, “Tumor antigen-specific T helper cells in cancer immunity and immunotherapy,” Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 721–728, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. J. P. Leddy, J. L. Falany, G. R. Kissel, S. T. Passador, and S. I. Rosenfeld, “Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1672–1680, 1993. View at Google Scholar · View at Scopus
  58. R. N. Barker, A. M. Hall, G. R. Standen, J. Jones, and C. J. Elson, “Identification of T-cell epitopes on the rhesus polypeptides in autoimmune hemolytic anemia,” Blood, vol. 90, no. 7, pp. 2701–2715, 1997. View at Google Scholar · View at Scopus
  59. F. J. Ward, A. M. Hall, L. S. Cairns et al., “Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia,” Blood, vol. 111, no. 2, pp. 680–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. M. Hall, O. M. Zamzami, N. Whibley et al., “Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia,” Haematologica, vol. 97, no. 10, pp. 1494–1500, 2012. View at Publisher · View at Google Scholar
  61. L. Xu, T. Zhang, Z. Liu, Q. Li, Z. Xu, and T. Ren, “Critical role of Th17 cells in development of autoimmune hemolytic anemia,” Experimental Hematology, vol. 40, no. 12, pp. 994.e4–1004.e4, 2012. View at Publisher · View at Google Scholar
  62. A. van Royen-Kerkhof, E. A. Sanders, V. Walraven et al., “A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcγRIIA transgenic mice,” British Journal of Haematology, vol. 130, no. 1, pp. 130–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Wood, “Immunotherapy for primary immunodeficiency diseases,” Medical Clinics of North America, vol. 96, no. 3, pp. 433–454, 2012. View at Google Scholar
  64. I. Genty, M. Michel, O. Hermine, A. Schaeffer, B. Godeau, and H. Rochant, “Characteristics of autoimmune haemolytic anemias in adults: retrospective analysis of 83 casess,” Revue de Medecine Interne, vol. 23, no. 11, pp. 901–909, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. J. R. Passweg and M. Rabusin, “Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias,” Autoimmunity, vol. 41, no. 8, pp. 660–665, 2008. View at Publisher · View at Google Scholar · View at Scopus